- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EVAXION Aktie jetzt für 0€ handeln | |||||
| Di | Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress | 274 | GlobeNewswire (Europe) | Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio... ► Artikel lesen | |
| Di | Evaxion A/S - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 07.05. | Evaxion announces business update and first quarter 2026 financial results | 329 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business update... ► Artikel lesen | |
| 04.05. | Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 | 312 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, will provide a business... ► Artikel lesen | |
| 04.05. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.04. | Evaxion promotes Birgitte Rønø to dual CSO and COO role | 3 | Investing.com | ||
| 27.04. | Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer | 418 | GlobeNewswire (Europe) | Management remit expansion reflecting organization alignment to maximize external engagement and strategy execution
COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"),... ► Artikel lesen | |
| 27.04. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.04. | Positive Studiendaten zu Krebsimpfstoff lassen Evaxion-Aktie um 8 % steigen | 2 | Investing.com Deutsch | ||
| 17.04. | Evaxion stock jumps 8% on positive cancer vaccine trial data | 1 | Investing.com | ||
| 17.04. | Evaxion: Krebsimpfstoff erzielt 86 % Immunantwort in Phase-2-Studie | 2 | Investing.com Deutsch | ||
| 17.04. | Evaxion reports 86% immune response rate in cancer vaccine trial | 2 | Investing.com | ||
| 17.04. | Evaxion's AI-Immunology platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial | 463 | GlobeNewswire (Europe) | New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune responseThe results reinforce that Evaxion's pioneering... ► Artikel lesen | |
| 17.04. | Evaxion: KI-Plattform identifiziert Impfstoffziele bei Hirntumoren | 2 | Investing.com Deutsch | ||
| 17.04. | Evaxion presents AI platform data for glioblastoma vaccine design | 2 | Investing.com | ||
| 17.04. | New data demonstrates the unique scalability of Evaxion's AI-Immunology platform in glioblastoma | 389 | GlobeNewswire (Europe) | Data analysis conducted in collaboration with a leading academic medical center shows that AI-Immunology enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can... ► Artikel lesen | |
| 16.04. | Evaxion concludes Annual General Meeting | 278 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, held its Annual General... ► Artikel lesen | |
| 16.04. | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.04. | Evaxion completes phase 2 trial extension for cancer vaccine | 1 | Investing.com | ||
| 07.04. | Evaxion schließt Phase-2-Studienverlängerung für Krebsimpfstoff ab | 6 | Investing.com Deutsch |
1 2 3 4 Weiter >>
80 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,75 | -0,25 % | Alarm bei BioNTech! Milliarden bei Hensoldt! Kaufchance bei North Arrow Minerals! | "Erst kaufen, dann killen", so reagierte Tübingens Oberbürgermeister Boris Palmer auf die geplanten Standortschließungen von BioNTech. Denn in diesem Rahmen sollen praktisch alle Standorte der erst... ► Artikel lesen | |
| EVOTEC | 4,700 | +3,52 % | Mit guten Konzepten und Entspannung im Nahost-Konflikt voran! MustGrow, K+S, Evotec und Novo Nordisk im Fokus | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Was für eine Nachricht: Einigung zwischen USA und dem Iran - Märkte plus 2 % in nur 1 Minute! So schnell kann es gehen. Für Investoren... ► Artikel lesen | |
| QIAGEN | 28,590 | +0,85 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| PAION | 0,073 | -24,48 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| AMGEN | 288,15 | +0,28 % | Piper Sandler lowers Amgen stock price target on rare disease outlook | ||
| NOVAVAX | 7,900 | +0,13 % | Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes | ||
| STRYKER | 261,40 | +1,32 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders... ► Artikel lesen | |
| BIOGEN | 165,50 | -5,30 % | Biogen Inc.: Biogen Completes Acquisition of Apellis Pharmaceuticals | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,685 | -3,06 % | 1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? | ||
| OCUGEN | 1,256 | +0,32 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,890 | -2,43 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| CG ONCOLOGY | 69,54 | -6,03 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| ASSERTIO | 23,315 | -0,02 % | Assertio Holdings, Inc. to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash | All-Cash Tender Offer of $23.50 per share or $166.4 Million
Offer Represents 30.6% Premium to Original Agreement with Garda Therapeutics AND 75.8% Premium to Unaffected Price
LAKE FOREST, Ill.--(BUSINESS... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,140 | -3,46 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| RELAY THERAPEUTICS | 12,775 | -3,37 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) |
Das Unternehmen EVAXION A/S ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,230 (-5,39 %) liegt der Kurs bei 4,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.